Drug companies to pay the FDA $100 million in additional fees. The upside (or is it?): 2,000 regulators get to keep their job and new drugs will continue to funnel into the market. The downside: the FDA will increase its staff and drug companies get additional face time during the drug review process. The last PDUFA reauthorization in 2007 was highly disputed when the FDA failed to monitor dangerous drugs such as Vioxx.
Learn more about SSRI Birth Defects